.jpg "SCYNEXIS (NASDAQ: SCYX)")
In a report released yesterday, Jason McCarthy from Maxim Group assigned a Buy rating to SCYNEXIS (SCYX), with a price target of $17.00. The company’s shares closed last Wednesday at $6.81.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 32.2% and a 52.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and Interpace Diagnostics Group.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SCYNEXIS with a $31.75 average price target, which is a 370.4% upside from current levels. In a report issued on December 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
Based on SCYNEXIS’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $909K. In comparison, last year the company had a GAAP net loss of $7.94 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
